Select Bibliography

Filter by any of these (after searching):

CALGB-51101

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 3 items

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in CALGB 51101 (Alliance)

Batchelor, T , Giri, S , Stark, A , Bartlett, N , Hsi, E , Cheson, B ... - ASCO - J Clin Oncol. - 2020

Abstract - Primary - Primary - Lymphoma - CALGB-51101

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 [Alliance]

Batchelor, Tracy T. , Giri, Sharmila , Ruppert, Amy S. ... - ASCO - J Clin Oncol - 2021

Abstract - Primary - Primary - Lymphoma - CALGB-51101

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 [Alliance]

Batchelor, Tracy T. , Giri, Sharmila , Ruppert, Amy S. ... - ICBTRT - - 2021

Abstract - Primary - Primary - Lymphoma - CALGB-51101